July is UV Awareness Month

Gaurav Singh, MD, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.

Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.

Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.